Use of aspirin for primary and secondary prevention of cardiovascular disease in diabetic patients in an ambulatory care setting in Spain

BMC Family Practice

Volumn 8, Issue , 2007, Pages

  Sicras Mainar, Antoni ^a   Navarro Artieda, Ruth ^a   Rejas Gutiérrez, Javier ^b   Fernández de Bobadilla, Jaime ^b   Frías Garrido, Xavier ^a   Ruiz Riera, Rafael ^a  

^a Badalona Serveis Assistencials SA   (Spain)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CHOLESTEROL; GLYCOSYLATED HEMOGLOBIN; ANTITHROMBOCYTIC AGENT;

ADULT; AGED; AMBULATORY CARE; ANTICOAGULATION; ARTICLE; BLOOD PRESSURE MONITORING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHI SQUARE TEST; CHOLECYSTOKININ BLOOD LEVEL; COMORBIDITY; DIABETES MELLITUS; DIABETIC PATIENT; DRUG USE; FEMALE; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRIMARY PREVENTION; RETROSPECTIVE STUDY; SECONDARY PREVENTION; SPAIN; CLINICAL TRIAL; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY; PREVALENCE; TREATMENT OUTCOME;

AGED; AMBULATORY CARE; ASPIRIN; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PREVALENCE; RETROSPECTIVE STUDIES; SPAIN; TREATMENT OUTCOME;

EID: 36649028502     PISSN: None     EISSN: 14712296     Source Type: Journal    
DOI: 10.1186/1471-2296-8-60     Document Type: Article

References (38)

1. Intense management of diabetes mellitus: role of glucose control and antiplatelet agents. S Mudaliar, J Clin Pharmacol 2004 44 414 22 10.1177/0091270004263045 15051750
2. revention of cardiovascular complications of diabetes mellitus by aspirin. C Nobles-James EA James JR Sowers, Cardiovasc Drug Rev 2004 22 215 26 15492769
3. Aspirin therapy in diabetes. American Diabetes Association, Diabetes Care 2004 27 S72 S3 10.2337/diacare.27.2007.S72 14693931
4. Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. ETDRS Investigators, JAMA 1992 268 1292 300 10.1001/jama.268.10.1292 1507375
5. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. L Hansson A Zanchetti SG Carruthers B Dahlof D Elmfeldt S Julius J Menard KH Rahn H Wedel S Westerling, Lancet 1998 351 1755 62 10.1016/S0140-6736(98)04311-6 9635947
6. Final report on the aspirin component of the ongoing Physicians' Health Study. Steering Committee of the Physicians' Health Study Research Group, N Engl J Med 1989 321 129 35 2664509
7. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force. M Hayden M Pignone C Phillips C Mulrow, Ann Intern Med 2002 136 161 72 11790072
8. AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association Science Advisory and Coordinating Committee. TA Pearson SN Blair SR Daniels RH Eckel JM Fair SP Fortmann BA Franklin LB Goldstein P Greenland SM Grundy Y Hong NH Miller RM Lauer IS Ockene RL Sacco JF Sallis Jr SC Smith Jr NJ Stone KA Taubert, Circulation 2002 106 388 91 10.1161/01.CIR.0000020190.45892.75 12119259
9. Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials. PS Sanmuganathan P Ghahramani PR Jackson EJ Wallis LE Ramsay, Heart 2001 85 265 71 11179262 10.1136/heart.85.3.265
10. Metaanálisis de la evidencia científica sobre la utilidad de la toma esporádica de ácido acetilsalicílico en la prevención de enfermedad coronaria. G Pueyo R Elosua J Marrugat, Med Clin (Barc) 2002 118 166 9 11851991
11. Empleo de antiagregantes en la prevención primaria y secundaria cardiovascular del diabético en el medio urbano y rural del área de León. J López S Escudero AM González A Mencía LE García B Morán, Aten Primaria 2003 31 361 5 12716570
12. Consumo de ácido acetilsalicílico en pacientes con diabetes mellitus. E Esmatjes C Castell J Franch E Puigoriol R Hernáez, Med Clin (Barc) 2004 122 96 8 10.1157/13056809 14746698
13. Consumo de ácido acetilsalicílico en pacientes con diabetes mellitus. FJ de Abajo LA Garcia Rodriguez, Med Clin (Barc) 2004 123 236 10.1157/13064431 15282080
14. Aspirin for primary prevention in patients with diabetes mellitus. KX Nguyen JS Marinac C Sun, Fam Med 2005 37 112 7 15690251
15. Underuse of aspirin in type 2 diabetes mellitus: prevalence and correlates of therapy in rural Canada. JA Klinke JA Johnson LM Guirguis EL Toth TK Lee RZ Lewanczuk SR Majumdar, Clin Ther 2004 26 439 46 10.1016/S0149-2918(04) 90040-9 15110137
16. Changing aspirin use in patients with Type 2 diabetes in the UKPDS. CA Cull HA Neil RR Holman, Diabet Med 2004 21 1368 71 10.1111/j.1464-5491.2004. 01328.x 15569143
17. Aspirin use among adults with diabetes: estimates from the Third National Health and Nutrition Examination Survey. DB Rolka A Fagot-Campagna KM Narayan, Diabetes Care 2001 24 197 201 10.2337/diacare.24.2.197 11213865
18. Application of U.S. guidelines in other countries: aspirin for the primary prevention of cardiovascular events in Japan. T Morimoto T Fukui TH Lee K Matsui, Am J Med 2004 117 459 68 10.1016/j.amjmed.2004.04.017 15464702
19. Clasificación Internacional de la Atención Primaria CIAP-2. Clasificación de razones de consulta. H Lamberts M Wood, Barcelona, Masson/SG 1990
20. Estimation of the concentration of low-density lipoproteins cholesterol in plasma without use of the preparative ultracentrifuge. WT Friedewald RJ Levy DS Frederickson, Clin Chem 1972 18 499 502 4337382
21. Diabetes mellitus y riesgo cardiovascular. Recomendaciones del Grupo de Trabajo Diabetes Mellitus y Enfermedad Cardiovascular de la Sociedad Espãola de Diabetes. Grupo de Trabajo Diabetes mellitus, Clin Invest Arterioscl 2004 1 74 8
22. Infrautilización del ácido acetilsalicílico en la prevención cardiovascular del paciente con diabetes mellitus. H Bueno, Med Clin (Barc) 2004 122 101 3 10.1157/13056808 14746700
23. Use of acetylsalicylic acid by physicians and in the community. J Mahon K Steel BG Feagan A Laupacis LL Pederson, CMAJ 1991 145 1107 16 1751930
24. Use of aspirin to reduce risks of cardiovascular disease in patients with diabetes: clinical and research challenges. CH Hennekens GL Knatterud MA Pfeffer, Diabetes Care 2004 27 2752 4 10.2337/diacare.27.11.2752 15505018
25. Dealing with medical practice variation: aproposal for action. J Wenberg, Health Aff 1984 3 6 31 10.1377/hlthaff.3.2.6
26. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. SM Haffner S Lehto T Ronnemaa K Pyorala M Laakso, N Engl J Med 1998 339 229 34 10.1056/NEJM199807233390404 9673301
27. Lipoprotein abnormalities and their consequences for patients with type 2 diabetes. AJ Krentz, Diabetes Obes Metab 2003 5 Suppl 1 S19 27 10.1046/j.1462-8902.2003.0310.x 14984018
28. Evaluación del cumplimiento de los objetivos de control metabólico de la diabetes mellitus tipo 2. Estudio TranSTAR. H de la Calle A Costa J Díez-Espino J Franch A Goday, Med Clin (Barc) 2003 120 446 50 10.1157/13045520 12689550
29. Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial. M Sacco F Pellegrini MC Roncaglioni F Avanzini G Tognoni A Nicolucci on behalf of the PPP Collaborative Group, Diabetes Care 2003 26 3264 72 10.2337/diacare.26.12.3264 14633812
30. Prevention of vascular events in diabetes mellitus: which "antithrombotic" therapy? A Ceriello E Motz, Diabetologia 1996 39 1405 6 10.1007/s001250050591 8933013
31. Stroke: strategies for primary prevention. JA Ezekowitz SE Straus SR Majumdar FA McAlister, Am Fam Physician 2003 68 2379 86 14705756
32. Antiplatelet agents for the prevention of cardiovascular disease in diabetes mellitus. JA Colwell, Am J Cardiovasc Drugs 2004 4 87 106 10.2165/00129784-200404020-00003 15049721
33. Evidence based medicine: what it is and what it isn't. D Sackett W Rosenberg J Gray Rb Haynes WS Richardson, BMJ 1996 312 71 2 8555924
34. Stroke: strategies for primary prevention. JA Ezekowitz SE Straus SR Majumdar FA McAlister, Am Fam Physician 2003 68 2379 86 14705756
35. Role of antiplatelet drugs in the prevention of cardiovascular events. M Tendera W Wojakowski, Thromb Res 2003 110 355 9 10.1016/j.thromres.2003.08.003 14592562
36. Diabetes mellitus: a cardiovascular disease. R Candido P Srivastava ME Cooper LM Burrell, Curr Opin Investig Drugs 2003 4 1088 94 14582453
37. The platelet in diabetes: focus on prevention of ischemic events. JA Colwell RW Nesto, Diabetes Care 2003 26 2181 8 10.2337/diacare.26.7.2181 12832332
38. Aspirin dose for prevention of cardiovascular disease in diabetics. SN Nowak LA Jaber, Ann Pharmacother 2003 37 116 21 10.1345/aph.1C101 12503945